<DOC>
	<DOCNO>NCT00551096</DOCNO>
	<brief_summary>Zactima use study determine high dose give safely well side effect Zactima combination two FDA approve drug ; gemcitabine capecitabine . This combination give patient advance solid tumor . Once high dose combination determine , additional patient biliary cancer ( cholangiocarcinomas gallbladder cancer ) locally advanced metastatic pancreatic cancer treat high determine dose study .</brief_summary>
	<brief_title>Gemcitabine/Capecitabine/ZD6474 Advanced Solid Tumors</brief_title>
	<detailed_description>This phase I study access novel regimen use multi-targeted anti-angiogenic agent target tyrosine kinase vascular endothelial growth factor ( VEGF ) receptor 2 epidermal growth factor receptor ( EGFR ) combination cytotoxic agent : gemcitabine capecitabine . The rationale base observation additive / synergistic effect cytotoxic agent combine angiogenesis inhibitor . There also evidence EGFR mediate signal pathway potent stimulators VEGF production . Also concept dual target tumor endothelial cell may provide encourage result .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Age 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ( measure ability perform everyday task ) Life expectancy least three month Blood sample test may apply test eligibility . Uncontrolled illness ( example , current infection heart condition ) Abnormal laboratory test ( blood urine test ) Pregnant breastfeed woman Further exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Biliary Pancreatic Malignancies</keyword>
</DOC>